- Home
- SPGI vs SNY Comparison
SPGI vs SNY Comparison
Compare SPGI & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPGI | SNY |
|---|---|---|
| Founded | 1860 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.6B | 104.5B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | SPGI | SNY |
|---|---|---|
| Price | $415.52 | $44.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 5 |
| Target Price | ★ $558.33 | $58.00 |
| AVG Volume (30 Days) | 1.9M | ★ 2.3M |
| Earning Date | 04-28-2026 | 04-23-2026 |
| Dividend Yield | 0.90% | ★ 3.47% |
| EPS Growth | ★ 18.70 | N/A |
| EPS | ★ 4.69 | N/A |
| Revenue | ★ $6,063,000,000.00 | N/A |
| Revenue This Year | $9.66 | $3.49 |
| Revenue Next Year | $7.35 | $6.10 |
| P/E Ratio | $90.94 | ★ $6.14 |
| Revenue Growth | ★ 7.10 | N/A |
| 52 Week Low | $381.61 | $42.28 |
| 52 Week High | $579.05 | $52.68 |
Technical Indicators
Market Signals| Indicator | SPGI | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 45.74 | 51.69 |
| Support Level | $404.19 | $42.30 |
| Resistance Level | $450.12 | $48.76 |
| Average True Range (ATR) | 9.75 | 0.60 |
| MACD | 0.75 | 0.16 |
| Stochastic Oscillator | 28.47 | 75.00 |
Price Performance
Historical ComparisonAbout SPGI S&P Global Inc.
S&P Global provides data and benchmarks to capital and commodity market participants. Its ratings business is the largest credit rating agency in the world and S&P's largest segment by profitability. S&P's largest segment by revenue is market intelligence, which provides desktop, data and advisory solutions, enterprise solutions, and credit/risk solutions mostly in the financial-services industry. S&P's other segments include energy (formerly commodity insights, this segment includes Platts and other data), mobility (Carfax), and indexes. S&P plans to spin off mobility in 2026.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.